Toll-like receptors: a family of innate sensors of danger that alert and drive immunity

被引:0
作者
Montero Vega, M. T. [1 ]
de Andres Martin, A. [2 ]
机构
[1] Hosp Ramon & Cajal, Serv Bioquim Invest, E-28034 Madrid, Spain
[2] Hosp Ramon & Cajal, Serv Inmunol, E-28034 Madrid, Spain
关键词
Toll-like receptors; Innate immunity;
D O I
暂无
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
The innate immune system possesses a network of germline-encoded receptors that recognize microbial molecular motifs and endogenous molecules produced by injured tissues and set in motion a defensive response which adapts to the damage that has occurred. This network includes Toll-like receptors (TLRs), a family of transmembrane receptors that recognize a wide spectrum of ligands at the cell surface and in the lumen of intracellular vesicles. Recognition of ligands by TLRs induces the recruitment of different cytoplasmic adaptor molecules and initiates signalling pathways which ultimately lead to the activation of transcriptional factors such as NF-kappa B, IRF1/3/5/7, or AP-1. These factors are involved in the expression of inflammatory cytokines, chemokines, type 1 interferons, co-stimulatory molecules, and other factors of the effector response. TLRs regulate many aspects of both innate and adaptive immunity. To prevent an inappropriate or an overactive immune response, a complex network of molecules negatively regulates TLRs and their associated signalling pathways. TLRs are currently viewd as important targets for the development of new vaccines and innovative therapies which may help prevent or treat disorders such as cancer, allergy, autoimmunity, obesity, atherosclerosis, and other inflammatory diseases.
引用
收藏
页码:347 / 357
页数:11
相关论文
共 112 条
[11]  
Brikos Constantinos, 2008, V183, P21
[12]   ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance [J].
Brint, EK ;
Xu, DM ;
Liu, HY ;
Dunne, A ;
McKenzie, ANJ ;
O'Neill, LAJ ;
Liew, FY .
NATURE IMMUNOLOGY, 2004, 5 (04) :373-379
[13]   Inhibition of interleukin 1 receptor/toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4 [J].
Burns, K ;
Janssens, S ;
Brissoni, B ;
Olivos, N ;
Beyaert, R ;
Tschopp, J .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (02) :263-268
[14]  
Carmody RJ, 2007, CELL MOL IMMUNOL, V4, P31
[15]   Triad3A, an E3 ubiquitin-protein ligase regulating Toll-like receptors [J].
Chuang, TH ;
Ulevitch, RJ .
NATURE IMMUNOLOGY, 2004, 5 (05) :495-502
[16]   Pathological role of Toll-like receptor signaling in cerebral malaria [J].
Coban, Cevayir ;
Ishii, Ken J. ;
Uematsu, Satoshi ;
Arisue, Nobuko ;
Sato, Shintaro ;
Yamamoto, Masahiro ;
Kawai, Taro ;
Takeuchi, Osamu ;
Hisaeda, Hajime ;
Horii, Toshihiro ;
Akira, Shizuo .
INTERNATIONAL IMMUNOLOGY, 2007, 19 (01) :67-79
[17]   Achieving stability of lipopolysaccharide-induced NF-κB activation [J].
Covert, MW ;
Leung, TH ;
Gaston, JE ;
Baltimore, D .
SCIENCE, 2005, 309 (5742) :1854-1857
[18]   TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity [J].
Creagh, Emma M. ;
O'Neill, Luke A. J. .
TRENDS IN IMMUNOLOGY, 2006, 27 (08) :352-357
[19]   Plant pathogens and integrated defence responses to infection [J].
Dangl, JL ;
Jones, JDG .
NATURE, 2001, 411 (6839) :826-833
[20]   Preparing for first-in-man studies: the challenges for translational immunology post-TGN1412 [J].
Dayan, C. M. ;
Wraith, D. C. .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2008, 151 (02) :231-234